1. Home
  2. NVAX vs DGII Comparison

NVAX vs DGII Comparison

Compare NVAX & DGII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • DGII
  • Stock Information
  • Founded
  • NVAX 1987
  • DGII 1985
  • Country
  • NVAX United States
  • DGII United States
  • Employees
  • NVAX N/A
  • DGII N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • DGII Computer peripheral equipment
  • Sector
  • NVAX Health Care
  • DGII Technology
  • Exchange
  • NVAX Nasdaq
  • DGII Nasdaq
  • Market Cap
  • NVAX 1.3B
  • DGII 1.3B
  • IPO Year
  • NVAX 1995
  • DGII N/A
  • Fundamental
  • Price
  • NVAX $6.56
  • DGII $31.14
  • Analyst Decision
  • NVAX Buy
  • DGII Hold
  • Analyst Count
  • NVAX 6
  • DGII 3
  • Target Price
  • NVAX $15.33
  • DGII $35.67
  • AVG Volume (30 Days)
  • NVAX 5.1M
  • DGII 160.9K
  • Earning Date
  • NVAX 08-06-2025
  • DGII 08-06-2025
  • Dividend Yield
  • NVAX N/A
  • DGII N/A
  • EPS Growth
  • NVAX N/A
  • DGII 196.64
  • EPS
  • NVAX 2.97
  • DGII 1.13
  • Revenue
  • NVAX $1,254,962,000.00
  • DGII $418,624,000.00
  • Revenue This Year
  • NVAX $52.02
  • DGII $1.81
  • Revenue Next Year
  • NVAX N/A
  • DGII $4.34
  • P/E Ratio
  • NVAX $2.21
  • DGII $27.61
  • Revenue Growth
  • NVAX 25.92
  • DGII N/A
  • 52 Week Low
  • NVAX $5.01
  • DGII $20.17
  • 52 Week High
  • NVAX $15.22
  • DGII $37.07
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 40.82
  • DGII 33.09
  • Support Level
  • NVAX $6.93
  • DGII $33.01
  • Resistance Level
  • NVAX $8.46
  • DGII $34.83
  • Average True Range (ATR)
  • NVAX 0.34
  • DGII 0.93
  • MACD
  • NVAX -0.08
  • DGII -0.23
  • Stochastic Oscillator
  • NVAX 9.52
  • DGII 5.87

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.

Share on Social Networks: